Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heparin bladder rinse may cut recurrent UTIs in women

NCT ID NCT02246270

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether putting heparin directly into the bladder can reduce the number of urinary tract infections (UTIs) in women who get them often. 34 women with recurrent UTIs received either heparin or a placebo (saline) bladder wash. The study measured how many UTIs they had over 6 months and how long it took for another infection to occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Heparin (bladder instillation)
What this could lead to
If it works, this could offer a new option to prevent recurrent urinary tract infections in women.
What could go wrong
This is a very early, small trial with only 34 participants. The results may not apply to everyone, and heparin's effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

34 people

The number who actually took part.

Started

Nov 2017

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-85 with history of recurrent urinary tract infections. * Definition of Recurrent UTI: if experienced either more than 3 symptomatic UTI episodes in the past year (including the index infection) or 2 such episodes in the past 6 months. * Definition of UTI: \>103 cfu/mL of a uropathogen in midstream urine culture from a woman experiencing more than 2 symptoms of cystitis (dysuria, urgency, frequency, suprapubic pain, or hematuria) or, in the absence of a culture, demonstration of pyuria on urinalysis and more than 2 urinary symptoms, as well as complete and rapid resolution of symptoms in response to antibiotic therapy for UTI. Exclusion Criteria: * Taking any anticoagulant such as warfarin sodium, heparin * Taking any thrombolytic agent such as a tissue plasminogen activator or streptokinase * Known aneurysm, thrombocytopenia, hemorrhagic disease, hemophilia, gastrointestinal ulceration, polyps, or diverticula * Known hypersensitivity to heparin * History of, or currently has neurogenic bladder, pelvic irradiation or chemical cystitis * Presence of urethral, pelvic, or rectal carcinoma, Benign or malignant bladder tumors * Tuberculous cystitis, urinary schistosomiasis * Bladder or ureteral calculi, urethral or bladder obstruction, augmentation cystoplasty, cystectomy, supratrigonal denervation of the bladder (cystolysis), neurectomy, or implanted peripheral nerve stimulator that has affected bladder function; Microscopic hematuria as defined as \> 5 red blood cells (RBC) /high power field at baseline visit without a negative workup within the last year * Positive pregnancy test at the baseline visit, are pregnant or lactating, or are planning to become pregnant during the study period * Have history of uterine, cervical or vaginal cancer during the past 3 years * Clinically significant vaginitis at baseline visit

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent urinary tract infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Oklahoma-Tulsa OB/GYN Dept and OU-Physicians

    Tulsa, Oklahoma, 74135, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.